Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
'A prank': Israel Police detain suspect for shooting rubber bullets at Ashkelon kindergarten - 2Figure out How to Put resources into Lab Precious stones
- 3Gym tied to outbreak of obscure disease that spreads through mist
- 4Surge of off‑lease electric vehicles expected to drive down used EV prices
- 5Three killed as unfinished building collapses on church service in Ghana
- Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
- Eight arrested in joint Scotland and Spain gang raids
- America's Confided in Fridge in 2024
- An Aide On Upgrading Your FICO rating
- NASA's giant moon rocket, in photos
- The new queen of country music has no scandals and no gimmicks — and just broke a record set by Taylor Swift
- Doctor's orders? ‘Belly laugh at least two to five days a week'
- Vote in favor of Your Number one Smartwatch: Exactness and Style Matter
- 7 Powerful Methods for forestalling Telephone Overheating: Keep Your Gadget Cool
